Table 4.
Heart failure pharmaceutical treatment.
| Discharge n = 257 |
M6 n = 220 |
p value | |
|---|---|---|---|
| ACEIs/ARBs, n (%) | 235 (91.4%) | 173 (79.5%) | <0.001 |
| ▪ ≥50% of target dose, n (%) | 92 (41.8%) | 78 (45.1%) | 0.5 |
| ▪ Contra-indication or intolerant, n (%) | 22 (8.6%) | 25 (11.4%) | 0.5 |
| Beta-blockers, n (%) | 85 (33.1%) | 111 (50.5%) | <0.001 |
| ▪ ≥50% of target dose, n (%) | 10 (11.8%) | 40 (36.0%) | <0.001 |
| ▪ Contra-indication or intolerant, n (%) | 75 (29.2%) | 60 (27.3%) | NS |
| MRA, n (%) | 198 (77.0%) | 144 (65.5%) | <0.001 |
| ▪ ≥50% of target dose, n (%) | 178 (89.9%) | 138 (95.8%) | <0.001 |
| ▪ Contra-indication or intolerant, n (%) | 27 (10.5%) | 24 (10.9%) | NS |
| Diuretics, n (%) | 219 (85.2%) | 163 (74.1%) | <0.001 |
| ▪ ≥50% of target dose, n (%) | 175 (79.9%) | 124 (76.1%) | 0.5 |
| ▪ Contra-indication or intolerant, n (%) | 8 (3.1%) | 12 (5.5%) | NS |
| Ivabradine, n (%) | 23 (8.9%) | 44 (20.0%) | <0.001 |
| ▪ ≥50% of target dose, n (%) | 10 (43.5%) | 32 (72.7%) | <0.001 |
| ▪ Contra-indication or intolerant, n (%) | 102 (39.7%) | 88 (40.0%) | NS |
| Digoxin, n (%) | 84 (32.7%) | 73 (33.2%) | NS |
| Nitrate, n (%) | 102 (39.6%) | 76 (34.5%) | 0.005 |
| ▪ ISDN, n (%) | 42 (16.3%) | 36 (16.4%) | NS |
| ▪ ISMN, n (%) | 60 (23.3%) | 40 (18.1%) | 0.005 |
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ISDN: isosorbide dinitrate; ISMN: isosorbide mononitrate; MRA: mineralocorticoid receptor antagonist; NS: non statistical significance, p > 0.5.